Roth Capital Reiterates Buy On Aptose Biosciences Shares, $20 PT
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (NASDAQ:APTO) with a price target of $20.00.
Pantginis noted, “We are adjusting our price target to $20 from $2 to account for a recent reverse split and adjusted share counts and change of base year to our clinical NPV valuation model. Aptose is on the verge of what we consider to be a significant value driver for the company in the start of the Phase Ib study for APTO-253 in hematologic malignancies.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -8.2% and a 39.5% success rate. Pantginis is ranked #3316 out of 3349 analysts.